Tirzepatide-Associated Colonic Ischemia.

IF 0.6 Q4 GASTROENTEROLOGY & HEPATOLOGY
ACG Case Reports Journal Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI:10.14309/crj.0000000000001551
David Bayless, Jasraj Singh, Byoung Uk Park, Seth Sweetser
{"title":"Tirzepatide-Associated Colonic Ischemia.","authors":"David Bayless, Jasraj Singh, Byoung Uk Park, Seth Sweetser","doi":"10.14309/crj.0000000000001551","DOIUrl":null,"url":null,"abstract":"<p><p>The use of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has markedly increased for the treatment of weight loss and management of diabetes mellitus. Gastrointestinal adverse effects of GLP-1/GIP agonist therapy, including nausea, vomiting, and constipation, are common. We report a case of colonic ischemia in a 62-year-old woman which developed in association with the use of tirzepatide for weight loss. This report highlights a potential risk relationship between GLP-1/GIP agonist therapy and colonic ischemia and identifies risk factors that should be considered before prescribing tirzepatide.</p>","PeriodicalId":7394,"journal":{"name":"ACG Case Reports Journal","volume":"11 11","pages":"e01551"},"PeriodicalIF":0.6000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11540430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACG Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/crj.0000000000001551","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The use of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide has markedly increased for the treatment of weight loss and management of diabetes mellitus. Gastrointestinal adverse effects of GLP-1/GIP agonist therapy, including nausea, vomiting, and constipation, are common. We report a case of colonic ischemia in a 62-year-old woman which developed in association with the use of tirzepatide for weight loss. This report highlights a potential risk relationship between GLP-1/GIP agonist therapy and colonic ischemia and identifies risk factors that should be considered before prescribing tirzepatide.

替西帕肽相关性结肠缺血
胰高血糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素多肽(GIP)受体激动剂替塞帕肽在减肥和糖尿病治疗中的使用明显增加。GLP-1/GIP 受体激动剂治疗的胃肠道不良反应,包括恶心、呕吐和便秘很常见。我们报告了一例 62 岁女性结肠缺血病例,该病例与使用替扎帕肽减肥有关。本报告强调了 GLP-1/GIP 激动剂治疗与结肠缺血之间的潜在风险关系,并指出了在处方替扎帕肽之前应考虑的风险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACG Case Reports Journal
ACG Case Reports Journal GASTROENTEROLOGY & HEPATOLOGY-
自引率
14.30%
发文量
170
审稿时长
12 weeks
期刊介绍: ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信